Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its position in Abbott Laboratories (NYSE:ABT) by 1.5% during the third quarter, Holdings Channel reports. The fund owned 1,985,447 shares of the healthcare product maker’s stock after buying an additional 28,982 shares during the period. Abbott Laboratories makes up 1.9% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s investment portfolio, making the stock its 18th largest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Abbott Laboratories were worth $83,965,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Alpha Windward LLC boosted its position in shares of Abbott Laboratories by 22.7% in the second quarter. Alpha Windward LLC now owns 5,115 shares of the healthcare product maker’s stock valued at $201,000 after buying an additional 945 shares in the last quarter. Trust Co boosted its stake in Abbott Laboratories by 10.7% in the first quarter. Trust Co now owns 48,124 shares of the healthcare product maker’s stock valued at $2,013,000 after buying an additional 4,666 shares during the period. Exxonmobil Investment Management Inc. TX boosted its stake in Abbott Laboratories by 6.0% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 380,290 shares of the healthcare product maker’s stock valued at $14,949,000 after buying an additional 21,592 shares during the period. British Columbia Investment Management Corp boosted its stake in Abbott Laboratories by 0.4% in the second quarter. British Columbia Investment Management Corp now owns 679,187 shares of the healthcare product maker’s stock valued at $26,699,000 after buying an additional 2,600 shares during the period. Finally, Washington Trust Bank boosted its stake in Abbott Laboratories by 5.2% in the second quarter. Washington Trust Bank now owns 7,872 shares of the healthcare product maker’s stock valued at $309,000 after buying an additional 386 shares during the period. 72.12% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Shares of Abbott Laboratories (NYSE:ABT) opened at 38.07 on Thursday. Abbott Laboratories has a 12-month low of $36.00 and a 12-month high of $46.22. The company’s 50-day moving average is $39.99 and its 200-day moving average is $41.00. The stock has a market cap of $56.05 billion, a P/E ratio of 41.56 and a beta of 0.94.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 19th. The healthcare product maker reported $0.59 EPS for the quarter, topping the consensus estimate of $0.58 by $0.01. Abbott Laboratories had a net margin of 6.61% and a return on equity of 15.46%. The company earned $5.30 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the company posted $0.54 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, analysts expect that Abbott Laboratories will post $2.21 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, November 15th. Investors of record on Friday, October 14th were issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 2.73%. The ex-dividend date was Wednesday, October 12th. Abbott Laboratories’s dividend payout ratio is currently 114.29%.

TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. and international copyright law. The correct version of this article can be accessed at http://www.dailypolitical.com/2016/12/01/loring-wolcott-coolidge-fiduciary-advisors-llp-ma-increases-stake-in-abbott-laboratories-abt.html.

ABT has been the subject of several recent analyst reports. Bank of America Corp. reaffirmed a “buy” rating and set a $50.00 price objective on shares of Abbott Laboratories in a research report on Friday, August 12th. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Jefferies Group lifted their price objective on shares of Abbott Laboratories from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. BTIG Research reaffirmed a “buy” rating and set a $45.00 price objective on shares of Abbott Laboratories in a research report on Wednesday, August 10th. Finally, TheStreet raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, August 22nd. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $47.02.

In related news, Director Sally E. Blount purchased 5,100 shares of the firm’s stock in a transaction that occurred on Tuesday, November 1st. The stock was acquired at an average cost of $39.24 per share, for a total transaction of $200,124.00. Following the completion of the acquisition, the director now owns 20,143 shares in the company, valued at approximately $790,411.32. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Daniel Gesua Sive Salvadori sold 815 shares of the firm’s stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $41.71, for a total transaction of $33,993.65. Following the sale, the senior vice president now owns 59,791 shares of the company’s stock, valued at $2,493,882.61. The disclosure for this sale can be found here. Corporate insiders own 0.26% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

5 Day Chart for NYSE:ABT

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.